Key result
Obese patients with HFrEF were more likely to receive optimal medical therapy, including RASi/ARNi (91% vs 86%), compared to non-obese patients.
Why the study?
Does the use and prognostic association of heart failure pharmacological treatments differ between obese and non-obese patients with HFrEF?
Cohort (n=16,116)
Yes
Does the use and prognostic association of heart failure pharmacological treatments differ between obese and non-obese patients with HFrEF?
Obese patients with HFrEF are more likely to receive guideline-directed medical therapy than non-obese patients, and these therapies are associated with lower mortality regardless of obesity status.
Supports GDMT in obese HFrEF; extends observational data on consistent benefit but leaves open causality.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cappelletto et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=16,116). Obesity vs. Non-obese was evaluated on Use of renin-angiotensin system inhibitors (RASi) or angiotensin receptor-neprilysin inhibitors (ARNi). Obese patients with HFrEF were more likely to receive optimal medical therapy, including RASi/ARNi (91% vs 86%), compared to non-obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: